Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmaPrint

This article was originally published in The Tan Sheet

Executive Summary

Reports revenues of $11.9 mil. for the third quarter ended Dec. 31, with $7.5 mil. in licensing and development fees from its agreement with American Home Products. The company reported no revenue for the comparable quarter of 1997. PharmaPrint began licensing its herbal standardization technology for single entity herbals exclusively to AHP in 1997 for use in the company's Centrum Herbals line. The products were launched in November, with ads following in January ("The Tan Sheet" Jan. 11, p. 15). PharmaPrint records net income for the quarter of $2.7 mil., compared to a net loss of $4.3 mil. in last year's third quarter. The Irvine, Calif.-based firm plans to form a partnership for the launch of combination herb/vitamin products, possibly with AHP. An alliance for the development of a pharmaceutical product "also looks promising in the near-term," the firm says. PharmaPrint is conducting a Phase II clinical trial on a saw palmetto-derived drug for benign prostatic hypertrophy

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS089516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel